Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
doi: 10.1093/annonc/mdw410 29 CuiH
Notably, weight loss is strongly linked to improved OSA outcomes , making IRAs a potential dual-purpose therapy for patients with T2D and sleep apnea
We use the information we collect for purposes allowed by applicable laws, including to: We may combine the information we collect from you with information that we collect from other sources
Its anchor trials are SURMOUNT (tirzepatide for weight management, The New England Journal of Medicine , 2022) and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024), alongside STEP for semaglutide (NEJM 2021)
While cardiovascular benefits are still being studied, early research and patient outcomes are promising
After 3 months of treatment, a placebo-adjusted decrease of HbA1c up to 1.56% was seen, with placebo-adjusted body weight reduction of -8.96 kg
US$ 21.89
US$ 28.22
US$ 29.07
US$ 27.42
US$ 25.31
